Our Pricing

Tirzepatide UK Price - Online Prescription Service

Searching for transparent tirzepatide UK price online pharmacy options? At Cured Pharmacy, Mounjaro (tirzepatide) starts from £135.00 with all costs shown upfront before your free clinical consultation. Our UK-registered prescribers assess your suitability in under 3 minutes, and we dispense only genuine, MHRA-licensed medicines with discreet next-day delivery across the UK.

Understanding Tirzepatide UK Price and What You're Paying For

Tirzepatide is available in the UK under the brand name Mounjaro, a prescription-only medication licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities [1]. At Cured Pharmacy, Mounjaro starts from £135.00, which includes the medication, UK prescriber consultation, and discreet delivery to your door.

Unlike some online services that hide consultation fees or add delivery charges at checkout, we display the full cost before you begin your assessment. Your final price depends on the dose prescribed by your UK clinician following your medical assessment—typically starting at 2.5 mg weekly and titrating up to maintenance doses of 5 mg, 10 mg, or 15 mg based on your response and tolerability [1].

This transparent pricing model reflects our commitment to accessible healthcare. Superintendent Pharmacist Tarun Kumar (GPhC 2233073) oversees every prescription dispensed from our GPhC-registered pharmacy (9012511), ensuring you receive genuine UK-licensed medication with full regulatory oversight.

How Tirzepatide Works: The Dual-Agonist Advantage

Tirzepatide represents a significant advancement in weight management pharmacotherapy as the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for clinical use [2]. This dual mechanism distinguishes it from single-pathway GLP-1 agonists like semaglutide and liraglutide.

By activating both GIP and GLP-1 receptors, tirzepatide enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways [2]. In the landmark SURMOUNT-1 trial, participants receiving the 15 mg maintenance dose achieved an average body weight reduction of 22.5% over 72 weeks—substantially higher than results seen with single-agonist therapies [3].

The medication is administered via a pre-filled KwikPen injector once weekly, typically on the same day each week. Most patients begin noticing appetite reduction within the first few weeks, though optimal weight loss occurs gradually over several months as the dose is titrated upward under medical supervision.

Clinical Efficacy in Real-World UK Practice

Beyond controlled trial environments, UK prescribers report consistent patient outcomes when tirzepatide is combined with lifestyle modifications including a reduced-calorie diet and increased physical activity. The SURMOUNT-2 trial specifically examined patients with type 2 diabetes, demonstrating an average 15.7% weight reduction at 72 weeks alongside improved glycaemic control [4]. Subject to prescriber approval and individual response, tirzepatide may offer meaningful support for patients who have struggled with conventional weight management approaches.

Comparing Tirzepatide UK Price Across Treatment Options

When evaluating weight loss medications available through UK online pharmacies, patients often compare tirzepatide (Mounjaro) with semaglutide-based treatments like Wegovy and liraglutide products such as Saxenda. Each medication has distinct characteristics, dosing schedules, and clinical profiles that influence both suitability and cost-effectiveness.

Mounjaro's once-weekly injection schedule and superior weight loss outcomes in head-to-head trials make it an attractive option for patients seeking maximum efficacy [3]. However, your UK prescriber will consider your complete medical history, concurrent medications, previous treatment responses, and individual weight loss goals when recommending the most appropriate therapy.

At Cured Pharmacy, we stock the full range of MHRA-licensed weight management treatments, allowing your prescriber to select the option best suited to your clinical needs rather than limiting choices based on pharmacy inventory. All treatments require a valid UK prescription following online consultation with our clinical team.

Injectable vs Oral Weight Loss Medications

Beyond GLP-1 receptor agonist injections, UK patients may also be prescribed oral medications such as Orlistat (available as generic Orlistat, Xenical, Alli, or Orlos) depending on their BMI, medical history, and treatment preferences. Orlistat works through a different mechanism—inhibiting pancreatic lipase to reduce dietary fat absorption—and is taken three times daily with meals. Whilst injectable therapies typically produce greater weight loss in clinical trials, oral options may suit patients who prefer not to self-inject or have contraindications to GLP-1 agonists. Your UK prescriber will discuss all suitable options during your consultation.

Tirzepatide Prescription UK: The Online Consultation Process

Obtaining a tirzepatide prescription in the UK requires a clinical assessment by a registered prescriber, whether through your GP, a specialist weight management clinic, or a regulated online pharmacy service. At Cured Pharmacy, our streamlined digital consultation typically takes under 3 minutes to complete and is reviewed by UK-registered clinicians within hours.

The online assessment collects essential medical information including your current weight and height, previous weight loss attempts, existing health conditions, current medications, and any contraindications to GLP-1 therapy. Our prescribers evaluate your BMI, assess for conditions such as cardiovascular disease or diabetic retinopathy that may influence treatment choice, and determine whether tirzepatide is clinically appropriate for you.

If approved, your prescription is electronically transmitted to our GPhC-registered dispensary where our pharmacy team, under the supervision of Superintendent Pharmacist Tarun Kumar, prepares your medication for discreet next-day delivery. If tirzepatide is not suitable based on your medical assessment, our prescriber will explain why and may recommend alternative treatments from our weight loss range.

Mounjaro Dosing Schedule and What to Expect

Tirzepatide therapy follows a structured dose-escalation protocol designed to minimise gastrointestinal side effects whilst optimising weight loss efficacy. The standard UK prescribing schedule begins with 2.5 mg once weekly for 4 weeks, then increases to 5 mg weekly for at least 4 weeks [1]. Based on individual tolerance and weight loss response, your prescriber may further increase the dose in 2.5 mg increments at 4-week intervals, up to a maximum maintenance dose of 15 mg weekly.

Most patients experience mild to moderate gastrointestinal effects—particularly nausea, diarrhoea, and reduced appetite—during the initial weeks and following dose increases [1]. These effects typically diminish as your body adapts to each dose level. Staying well-hydrated, eating smaller meals, and avoiding high-fat foods can help manage these transient symptoms.

Your UK prescriber will schedule follow-up assessments to monitor your progress, evaluate weight loss trajectory, and determine appropriate dose adjustments. Patients who do not achieve at least 5% weight loss after 6 months at the maximum tolerated dose should discontinue treatment, as continued use is unlikely to produce clinically meaningful benefits [1].

Storage and Administration of Mounjaro Pens

Mounjaro KwikPens should be stored in a refrigerator at 2°C to 8°C until first use, then may be kept at room temperature (not exceeding 30°C) for up to 21 days if needed. Never freeze tirzepatide, and discard any pens that have been frozen. Each pen contains 4 doses and should be disposed of after 30 days, even if medication remains. Inject subcutaneously into your abdomen, thigh, or upper arm, rotating injection sites weekly to prevent lipodystrophy. Detailed administration instructions are provided with your medication, and our pharmacy team is available on (+44) 116 4646009 if you have questions.

Safety Considerations and Who Should Not Use Tirzepatide

Whilst tirzepatide demonstrates a favourable safety profile in clinical trials, certain patient populations should not use this medication. Absolute contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and known hypersensitivity to tirzepatide or any excipients [1]. Pregnant or breastfeeding women should not use tirzepatide, and the medication should be discontinued at least 2 months before planned conception due to its long half-life.

Patients with a history of pancreatitis, severe gastrointestinal disease, diabetic retinopathy, or renal impairment require careful evaluation before starting treatment. Tirzepatide may increase heart rate slightly and should be used cautiously in patients with cardiac arrhythmias [1]. If you develop severe abdominal pain, persistent vomiting, or visual changes whilst taking tirzepatide, contact your prescriber immediately.

Common side effects reported in clinical trials include nausea (affecting up to 33% of patients), diarrhoea, vomiting, constipation, dyspepsia, and injection site reactions [3]. These effects are generally mild to moderate and decrease over time. Hypoglycaemia is uncommon unless tirzepatide is used alongside insulin or sulfonylureas. Your UK prescriber will review your complete medication list to identify potential interactions before prescribing.

Scientific References

1. Electronic Medicines Compendium. (2024). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/14416
2. Frias, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
3. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
4. Garvey, W. T., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, 402(10402), 613–626. https://doi.org/10.1016/S0140-6736(23)01200-X

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment, lifestyle modifications, and individual metabolic factors.